Literature DB >> 12954220

Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus.

Robert H Mealey1, Baoshan Zhang, Steven R Leib, Matt H Littke, Travis C McGuire.   

Abstract

Equine infectious anemia virus (EIAV) is a lentivirus that causes persistent infections in horses. We hypothesized that high-avidity CTL specific for nonvariable epitopes might be associated with low viral load and minimal disease in EIAV-infected horses. To test this hypothesis, memory CTL (CTLm) responses were analyzed in two infected horses with high plasma viral loads and recurrent disease (progressors), and in two infected horses with low-to-undetectable viral loads and mild disease (nonprogressors). High-avidity CTLm in one progressor recognized an envelope gp90 epitope, and the data documented for the first time in EIAV that viral variation led to CTL escape. Each of the nonprogressors had high-to-moderate avidity CTLm directed against epitopes within Rev, including the nuclear export and nuclear localization domains. These results suggested that the epitope specificity of high- and moderate-avidity CTLm was an important determinant for disease outcome in the EIAV-infected horses examined.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954220      PMCID: PMC3342690          DOI: 10.1016/s0042-6822(03)00344-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  70 in total

1.  Genetic and biological variation in equine infectious anemia virus Rev correlates with variable stages of clinical disease in an experimentally infected pony.

Authors:  M Belshan; P Baccam; J L Oaks; B A Sponseller; S C Murphy; J Cornette; S Carpenter
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

2.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

3.  High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL.

Authors:  M Derby; M Alexander-Miller; R Tse; J Berzofsky
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

4.  Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys.

Authors:  D H Barouch; A Craiu; S Santra; M A Egan; J E Schmitz; M J Kuroda; T M Fu; J H Nam; L S Wyatt; M A Lifton; G R Krivulka; C E Nickerson; C I Lord; B Moss; M G Lewis; V M Hirsch; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Evolution and transmission of stable CTL escape mutations in HIV infection.

Authors:  P J Goulder; C Brander; Y Tang; C Tremblay; R A Colbert; M M Addo; E S Rosenberg; T Nguyen; R Allen; A Trocha; M Altfeld; S He; M Bunce; R Funkhouser; S I Pelton; S K Burchett; K McIntosh; B T Korber; B D Walker
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

6.  Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies.

Authors:  C Leroux; J K Craigo; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

7.  Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.

Authors:  D H Barouch; S Santra; M J Kuroda; J E Schmitz; R Plishka; A Buckler-White; A E Gaitan; R Zin; J H Nam; L S Wyatt; M A Lifton; C E Nickerson; B Moss; D C Montefiori; V M Hirsch; N L Letvin
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

8.  Real-time TaqMan PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA.

Authors:  C M Leutenegger; J Higgins; T B Matthews; A F Tarantal; P A Luciw; N C Pedersen; T W North
Journal:  AIDS Res Hum Retroviruses       Date:  2001-02-10       Impact factor: 2.205

9.  Equine infectious anaemia virus proteins with epitopes most frequently recognized by cytotoxic T lymphocytes from infected horses.

Authors:  Travis C McGuire; Steven R Leib; Scott M Lonning; Wei Zhang; Katherine M Byrne; Robert H Mealey
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

10.  Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses.

Authors:  A D Kelleher; C Long; E C Holmes; R L Allen; J Wilson; C Conlon; C Workman; S Shaunak; K Olson; P Goulder; C Brander; G Ogg; J S Sullivan; W Dyer; I Jones; A J McMichael; S Rowland-Jones; R E Phillips
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

View more
  23 in total

1.  CTL from EIAV carrier horses with diverse MHC class I alleles recognize epitope clusters in Gag matrix and capsid proteins.

Authors:  Chungwon Chung; Robert H Mealey; Travis C McGuire
Journal:  Virology       Date:  2004-09-15       Impact factor: 3.616

2.  Expression, refolding and preliminary X-ray crystallographic analysis of equine MHC class I molecule complexed with an EIAV-Env CTL epitope.

Authors:  Shugang Yao; Jianxun Qi; Jun Liu; Rong Chen; Xiaocheng Pan; Xiaoying Li; Feng Gao; Chun Xia
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-12-24

3.  Molecular detection, epidemiology, and genetic characterization of novel European field isolates of equine infectious anemia virus.

Authors:  Katia Cappelli; Stefano Capomaccio; Frank R Cook; Michela Felicetti; Maria Luisa Marenzoni; Giacomo Coppola; Andrea Verini-Supplizi; Mauro Coletti; Fabrizio Passamonti
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

Review 4.  High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors.

Authors:  Martha A Alexander-Miller
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

5.  Selecting peptides to optimize Th1 responses to an equine lentivirus using HLA-DR binding motifs and defined HIV-1 Th peptides.

Authors:  Darrilyn G Fraser; Robert H Mealey; Travis C McGuire
Journal:  Immunogenetics       Date:  2003-08-27       Impact factor: 2.846

6.  Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency.

Authors:  Sandra D Taylor; Steven R Leib; Wuwei Wu; Robert Nelson; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

7.  Lymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challenge.

Authors:  Darrilyn G Fraser; Steve R Leib; Bao Shan Zhang; Robert H Mealey; Wendy C Brown; Travis C McGuire
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

8.  Naturally arising point mutations in non-essential domains of equine infectious anemia virus Rev alter Rev-dependent nuclear-export activity.

Authors:  Wendy O Sparks; Karin S Dorman; Sijun Liu; Susan Carpenter
Journal:  J Gen Virol       Date:  2008-04       Impact factor: 3.891

9.  Cloning and large-scale expansion of epitope-specific equine cytotoxic T lymphocytes using an anti-equine CD3 monoclonal antibody and human recombinant IL-2.

Authors:  Robert H Mealey; Matt H Littke; Steven R Leib; William C Davis; Travis C McGuire
Journal:  Vet Immunol Immunopathol       Date:  2007-04-08       Impact factor: 2.046

10.  Dose-dependent modulation of CD8 and functional avidity as a result of peptide encounter.

Authors:  Charles J Kroger; Martha A Alexander-Miller
Journal:  Immunology       Date:  2007-05-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.